CollPlant Biotechnologies Ltd. (CLGN)
| Market Cap | 56.81M |
| Revenue (ttm) | 10.62M |
| Net Income (ttm) | -7.50M |
| Shares Out | 11.45M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | 15.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,805 |
| Open | 5.000 |
| Previous Close | 4.980 |
| Day's Range | 4.950 - 5.000 |
| 52-Week Range | 4.220 - 8.300 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+121.77%) |
| Earnings Date | Aug 22, 2024 |
About CLGN
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants f... [Read more]
Financial Performance
In 2023, CLGN's revenue was $10.96 million, an increase of 3565.22% compared to the previous year's $299,000. Losses were -$7.02 million, -58.53% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CLGN stock is "Strong Buy" and the 12-month stock price forecast is $11.0.
News
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing con...
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 millio...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 16, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics...
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Thursday, April 4, 2024, at 10:00 a.m. U.S. EDT - REHOVOT, Israel , March 26, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aestheti...
CollPlant Issues Letter to Shareholders
REHOVOT, Israel , Feb. 15, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its n...
CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its no...
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants
The current market for breast implants is estimated at $2.6 billion a year CollPlant expects the study to conclude by the first half of 2024 CollPlant plans to use findings from this study and success...
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023
Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement ...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Wednesday, November 29, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Nov. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesth...
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler
- Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Potential Products - REHOVOT, Israel , Nov. 1, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN...
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative
- As a new participant, the Company strengthens its commitment to operate sustainably and transition the regenerative and aesthetics medicine industry to sustainable alternatives - REHOVOT, Israel , S...
CollPlant to Present at the H.C. Wainwright Annual Growth Conference
REHOVOT, Israel , Sept. 5, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its no...
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million
Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaborat...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel, Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on Thursday, August 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Aug. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aestheti...
CollPlant Achieves Milestone and To Receive $10 Million From AbbVie in Accordance with its Regenerative Dermal Filler Product Collaboration Agreement
REHOVOT, Israel , June 26, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its no...
CollPlant Biotechnologies Announces First Quarter Financial Results For 2023 and Provides Corporate Update
Strong positive sales trajectory for rhCollagen based products Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombin...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on May 24, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 2, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine co...
Stratasys and CollPlant Unite Technologies to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs
EDEN PRAIRIE, Minn. & REHOVOT, Israel--(BUSINESS WIRE)---- $SSYS #3dprinting--Stratasys Ltd. (Nasdaq: SSYS) and CollPlant Biotechnologies (Nasdaq: CLGN) today announced a joint development and commerc...
Collplant Biotechnologies Announces Full-Year Financial Results For 2022 and Provides Corporate Update
Continued advancement of strategic collaboration with AbbVie to develop dermal and soft tissue filler products using CollPlant's recombinant human (rh)Collagen Additional large-animal study planned in...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2022 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
- Conference call to be held on March 29, 2023 at 10:00 am U.S. EDT - REHOVOT, Israel , March 14, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine...
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives
Study demonstrated progressive stages of tissue regeneration as highlighted by the formation of maturing connective tissue and neovascular networks within the implants No indication of adverse reactio...
CollPlant Enriches Portfolio of rhCollagen-Based Bioinks with Launch of Collink.3DTM 50L in Powder Form
Company's first bioink available in powder form provides enhanced operational flexibility to support a wide range of 3D bioprinting applications Collink.3D™ 50L strengthens CollPlant's platform of bio...
CollPlant Biotechnologies Provides Business Updates and Third Quarter 2022 Financial Results
Partnership with AbbVie to co-develop rhCollagen-based dermal and soft tissue fillers continues to advance according to plan Co-developing 3D bioprinted human intestine model ("Gut-on-a-Chip") for dru...